RxDoctor Payments Data

Steven Silver, MD

Cardiovascular Disease · Haddon Heights, NJNPI 1114970225

Payments from drug & device makers

$3,998in general payments, 2019–2025

Across 203 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$607
  • Amgen$316
  • Impulse Dynamics (USA) Inc.$241
  • Novartis$240
  • Pfizer$237
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,998 in reported general payments places this provider in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$699,265
Medicare patients
2,416
Services billed
5,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban187$248,846
EntrestoSacubitril/Valsartan28$54,381
XareltoRivaroxaban34$40,898
Repatha SureclickEvolocumab18$21,802
FarxigaDapagliflozin Propanediol11$18,951
Atorvastatin Calcium245$3,264
Metoprolol Succinate167$2,564
Ezetimibe54$1,869
Carvedilol100$1,110
Amlodipine Besylate108$899
Irbesartan21$863
Hydralazine Hcl24$840
Warfarin Sodium28$755
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$678
Metoprolol Tartrate61$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$237$248,846187 claims
NovartisEntresto$240$54,38128 claims
Johnson & JohnsonXarelto$102$40,89834 claims
AstraZenecaFarxiga$96$18,95111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Haddon Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →